Skip to content
PeptideHormone

A stronger beat at a lower pressure

Apelin is a peptide hormone that binds one receptor, APJ, and does two things most heart drugs cannot do together: it strengthens the heartbeat and it widens blood vessels, so pressure falls while output rises. The receptor was found five years before the peptide, a second natural ligand (elabela) shares it, and the native peptide lasts only minutes because ACE2 clips it. It is also a fat-cell hormone that rises with insulin, and an acute infusion lowers lung resistance in pulmonary arterial hypertension. What apelin is, why the short forms and the long form are not interchangeable, and why an infusion that works in people has not yet become a drug.

12 min read · reviewed November 2026

The short answer

Apelin is a peptide hormone. A 77-amino-acid precursor is cut into active pieces, and the piece that dominates in human blood and heart is thirteen amino acids long, capped by a pyroglutamate so enzymes nibble it more slowly. It binds one receptor, a class A G-protein-coupled receptor called the apelin receptor. The gene is still often called APJ; the recommended name is APLNR. When the peptide binds, the receptor couples mainly through Gi, which lowers cAMP inside the cell, and it can also recruit β-arrestin, which takes the receptor off the membrane.

The instruction that matters for the circulation is unusual. Apelin makes the heart contract more forcefully and, at the same time, relaxes blood vessels. Output goes up. Pressure goes down. Most drugs that strengthen a beat also raise the pressure the heart has to push against. Apelin loosens that load while it asks for a stronger stroke.

A receptor that waited five years for its peptide

The order of discovery runs the same way as ghrelin’s. In 1993 a human gene was cloned because its sequence looked like the angiotensin II receptor. The protein, named APJ, sat in the membrane with seven passes and ignored angiotensin. With no partner, it was filed as an orphan (O’Dowd et al., 1993).

In 1998 the partner was pulled out of bovine stomach extracts by the same laboratory method that had found several other peptide hormones: grind the tissue, fractionate, and test each fraction on cells expressing the orphan receptor. The active peptide was named apelin, for APJ endogenous ligand (Tatemoto et al., 1998). The resemblance to angiotensin was a family resemblance of the receiver, not of the message. Apelin does not bind the angiotensin receptor, and angiotensin does not bind APJ. In the circulation the two systems push in opposite directions: angiotensin tightens vessels and holds fluid; apelin loosens vessels and, in the hypothalamus, opposes vasopressin.

One precursor, several peptides

Calling it “apelin” hides a set. The precursor has paired basic residues that proteases read as cut sites, so the body can release the C-terminal 36, 17, or 13 amino acids, among other lengths. All of them activate the receptor. They do not activate it the same way. In cell assays the short forms are several-fold to tens-fold more potent than apelin-36 at the immediate G-protein signal. Apelin-36 is the one that holds β-arrestin on the receptor and drives internalization, which is a way of turning the receiver down after the message arrives.

The form that actually circulates is mostly [Pyr1]apelin-13: apelin-13 whose first glutamine has cyclized to pyroglutamate. That cap is why this is the durable species in plasma and in cardiac tissue. “Apelin” on a blood test, a vial, or a paper may mean any of these. The length changes both the strength of the signal and how fast the receptor disappears from the cell surface.

One precursor, three signalsPreproapelin77 amino acidsApelin-36Weaker Gi signal · holds β-arrestin · internalizes APJApelin-17Intermediate length · active at the same receptor[Pyr1]apelin-13Dominant in blood and heart · strongest quick signal
The cut is at the C-terminus. Shorter is more potent at the immediate G-protein signal. Apelin-36 stays on the receptor long enough to pull it inside. The pyroglutamate cap is what lets the 13-residue form persist in blood.

The same receptor has a second ligand

For fifteen years APJ had one known partner. Then a second peptide turned up in a region of the genome annotated as non-coding. One group named it elabela, from a zebrafish phenotype in which the embryo’s endoderm is late (Chng et al., 2013). Another named it Toddler, because without it embryonic cells fail to move (Pauli et al., 2014). It is one peptide, gene APELA, cleaved to a mature chain of about 32 amino acids and to shorter pieces that also activate APJ. Sequence identity with apelin is low, on the order of a quarter of the residues. The receptor reads a shape, not a shared sentence.

The developmental job belongs to elabela. In the fish, losing it wrecks heart formation at a stage when apelin is dispensable for that step. In adult mammals both ligands can dilate vessels and support contraction. A paper that says “the apelin receptor” is therefore ambiguous about which peptide was speaking. IUPHAR’s recommendation is to treat elabela as a second endogenous ligand and to call the receptor the apelin receptor anyway, after the ligand found first.

What the infusion does in a person

The human evidence is infusion evidence, because the peptide is gone in minutes. In healthy volunteers and in patients with chronic heart failure, intravenous [Pyr1]apelin-13 raised cardiac index and lowered mean arterial pressure and peripheral resistance. The same program found that forearm dilatation to apelin was preserved in heart failure, where dilatation to acetylcholine was not (Japp et al., 2010). The combination is the point. A pure inotrope that also vasoconstricts makes the heart work harder against a tighter circuit. Apelin asks for more stroke volume while it reduces the resistance downstream.

One peptide, two directions[Pyr1]apelin-13APJ · GiCardiac output risesstronger contraction · higher stroke volumePressure fallsvessels widen · peripheral resistance drops
The infusion result in volunteers and in heart failure: more output against less resistance. Most inotropes tighten the circuit they ask the heart to push against.

That effect survived the situations where a vasodilator often quits. During sodium depletion, and during a co-infusion of angiotensin II, the dilatation held. In twelve patients with chronic stable heart failure, a six-hour infusion kept cardiac index up and raised left ventricular ejection fraction for the length of the infusion (Barnes et al., 2013). These are pharmacological demonstrations, not outcomes trials. Nobody counted hospitalizations. The result says the receptor still answers in a failing heart, including while the renin-angiotensin system is switched on, which is the background of modern heart-failure treatment.

The same peptide has a second, older job in fluid balance. Apelin and vasopressin are made in the same magnocellular neurons of the hypothalamus. Vasopressin tells the kidney to keep water. Apelin inhibits those neurons, lowers vasopressin release, and increases urine output (De Mota et al., 2004). Water deprivation pushes the pair in opposite directions: vasopressin out into the blood, apelin held back in the cell. It is a push-pull pair inside one neuron, analogous to the way the natriuretic peptides oppose aldosterone from a different gland. The receptor class is different — APJ is an ordinary GPCR, the natriuretic receptors are guanylyl cyclases — and the peptide is different. The logic, shed the fluid, rhymes. Which receptor class a hormone uses still predicts the speed: a GPCR second messenger answers in seconds, which is why an apelin infusion is felt as hemodynamics and gone when the drip stops.

Where it comes from

Apelin is not a single-gland hormone. The precursor is expressed in endothelium, cardiomyocytes, adipocytes, and the magnocellular neurons that also make vasopressin. Tatemoto found it in stomach extracts because that is where the purification started, not because the stomach is its only source. Which tissue is speaking depends on the question: the heart and vessels for the hemodynamic infusion, the hypothalamus for water balance, fat for the insulin-linked rise, muscle for the signal that falls with age.

The circulating species is mostly the pyroglutamyl 13-mer, sequence written Pyr-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe. The C-terminal phenylalanine is not decorative. Cut it off and the receptor largely stops hearing the peptide.

The enzyme that erases it

ACE2 is usually introduced as the enzyme that converts angiotensin II into angiotensin-(1–7), a counterweight inside the renin-angiotensin system. When the enzyme was first screened against a panel of biological peptides, apelin-13 was hydrolyzed as efficiently as angiotensin II. In both cases ACE2 removes exactly one C-terminal residue (Vickers et al., 2002). For apelin that residue is the phenylalanine the receptor needs.

ACE2 takes one residue, and the signal stopsPyrRPRLSHKGPMPFACE2Phe off · what remains is quiet at the receptor
Same enzyme, same single-residue clip as angiotensin II. The amber residue is the one the receptor needs, which is why the native peptide has to be infused.

The practical consequence is the short half-life. Commercial blood tests have a second problem on top of the speed: many ELISAs do not distinguish the active 13-mer from inactive pieces of the same precursor, so a reported “apelin level” can mix a signal with its own wreckage. A selective mass-spectrometry assay, and a blood-collection protocol that stops the peptidases in the tube, were required before an infused concentration could even be measured in animals. Curiosity about a number on a lab report should start there.

Why it rises as fat rises

Fat cells make apelin and secrete it. In mice, expression in adipocytes and the level in blood rise together in obesities that come with high insulin, and they fall when insulin is absent. Insulin itself increases apelin expression in human and mouse fat cells. Obese patients in the same study had higher plasma apelin and higher insulin (Boucher et al., 2005).

That is the opposite of adiponectin, the fat hormone whose blood level falls as fat mass rises. Apelin behaves more like a readout of the insulin-rich fat depot than like a missing brake. Raising it further is not, on this evidence, a weight-loss strategy. The paper’s own question was whether the extra apelin is a friend or a foe. The answer is still split by tissue: useful as a vasodilator and an insulin-sensitizing signal in rodents, unproven as a drug in people, and already high in the state people most want to treat.

The lung, for an afternoon

Pulmonary arterial hypertension is a high-resistance lung circuit. A drug that dilates pulmonary vessels and raises cardiac output is the shape of the existing treatments, which is why apelin was taken into a catheterization lab. Nineteen patients received intravenous [Pyr1]apelin-13 or saline, in random order, during right-heart catheterization. Resistance in the lung vessels fell and cardiac output rose. The change was larger in the patients already taking a PDE5 inhibitor, a class that raises cGMP (Brash et al., 2018).

An afternoon of invasive measurements is the right size of claim. It shows the human pulmonary circulation still answers the peptide. It does not show that a course of treatment changes walking distance, hospitalizations, or survival. The trial registration is NCT01457170, and the paper stops at hemodynamics.

Fat, muscle, and the claim to be careful with

Apelin is also an adipokine and a contraction-induced muscle signal. Circulating levels track with insulin sensitivity in observational work, and in rodents apelin improves glucose handling. The result that travels furthest outside cardiology is newer: apelin production in muscle falls with age in people and in rodents, mice lacking the peptide or the receptor lose muscle function as they age, and putting the signal back in old mice improved strength through mitochondrial biogenesis, autophagy, and muscle stem cells (Vinel et al., 2018).

That is a strong animal paper plus a human association with exercise. It is not a trial of apelin as a treatment for sarcopenia. The page this site keeps separate from the mechanism applies here in full: a receptor story, even a clean one, is the bottom of the evidence ladder until someone measures the outcome in people and someone else repeats it.

Why the infusion is not a medicine

Native apelin is cleared within minutes, by peptidases that include ACE2, which clips the C-terminal phenylalanine the receptor needs. An infusion can hold a level. A drug has to survive a dose interval. The field’s answer has been the usual peptide playbook — stabilize the chain, bias it toward G protein and away from the arrestin that internalizes the receptor — and, in parallel, small molecules that occupy APJ without being peptides at all.

The small molecule that reached people first is AMG 986, a long-acting APJ agonist that activates both Gi and β-arrestin. In a phase 1b study, 182 participants in total, short courses were tolerated up to high daily doses in healthy volunteers and in a smaller heart-failure group. Ejection fraction and stroke volume ticked in a favorable direction on one imaging method and not cleanly on another. The investigators’ own summary was that clinically meaningful pharmacodynamic effects were not observed (Winkle et al., 2022). A first-in-human study is built to ask whether a dose is survivable and whether a signal appears. The signal did not appear at a size anyone would treat on.

So the state of the art is easy to state and easy to overread. The peptide is real, the receptor is real, and a controlled infusion changes human hemodynamics in the direction heart-failure physiology wants. No approved drug captures that. The gap is the half-life, the receptor’s habit of leaving the membrane, and the absence of an outcomes trial. Bullish on the physiology. The medicine is still a hypothesis.

  • One receptor, found first. APJ was cloned in 1993 as an angiotensin-receptor lookalike that did not bind angiotensin. Apelin, its ligand, was isolated in 1998.
  • Several lengths, one name. [Pyr1]apelin-13 is the main circulating form and the stronger G-protein agonist. Apelin-36 lasts on the receptor and internalizes it.
  • A second ligand. Elabela (Toddler) activates the same receptor, shares little sequence, and carries the embryonic heart-development job.
  • The human effect is an infusion. Acute infusions raise cardiac output and lower resistance in heart failure and in pulmonary arterial hypertension. The drip is the experiment.
  • Fat raises it; ACE2 erases it. Adipocytes secrete more apelin when insulin is high. ACE2 clips the C-terminal phenylalanine and the peptide goes quiet.
  • No approved drug. AMG 986 was tolerated and, over a short exposure, did not move heart function enough to matter. Mechanism is ahead of the page.

Educational reference on mechanism, summarized from public scientific literature and clinical-trial disclosures and simplified in places. Not individualized medical advice or a prescription. Where a dose or regimen appears it is reported from its source as research literacy — so you can read the evidence yourself — not an instruction to dose. Specific compounds and trials are named to explain the science; verify any claim against the linked primary sources.